Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 8/20 | 0.65 |
| ▸ | ABL1 | P00519 | 3/20 | 0.59 |
| ▸ | ABCB1 | P08183 | 3/20 | 0.59 |
| ▸ | BCR | P11274 | 3/20 | 0.59 |
| ▸ | ESR2 | Q92731 | 7/20 | 0.58 |
| ▸ | RXRA | P19793 | 1/20 | 0.56 |
| ▸ | RXRB | P28702 | 1/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.48 |
| ▸ | MMP3 | P08254 | 1/20 | 0.48 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.48 |
| ▸ | KDM1A | O60341 | 1/20 | 0.47 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.46 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28973449 | 0.86 | MMP3 (0.65) | ESR1ABL1ABCB1BCRESR2 | |
| SCHEMBL1958364 | 0.86 | RXRA (0.61) | ESR1RXRARXRBALOX5KDM1A | |
| SCHEMBL4246853 | 0.80 | AHR (0.62) | RXRARXRBALOX5 | |
| SCHEMBL1022492 | 0.80 | ESR1 (0.69) | ESR1ABL1ABCB1BCRESR2 | |
| SCHEMBL24617945 | 0.80 | ESR1 (1.00) | ESR1ABL1ABCB1BCRESR2 | |
| SCHEMBL920655 | 0.80 | ESR1 (1.00) | ESR1ABL1ABCB1BCRESR2 | |
| SCHEMBL187833 | 0.80 | ESR1 (1.00) | ESR1ABL1ABCB1BCRESR2 | |
| SCHEMBL29434858 | 0.78 | ESR1 (0.70) | ESR1ABL1ABCB1BCRESR2 | |
| SCHEMBL5379998 | 0.78 | ESR1 (0.70) | ESR1ABL1ABCB1BCRESR2 | |
| SCHEMBL10539436 | 0.77 | AHR (0.65) | ESR1ABL1ABCB1BCRESR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11389456-B2 | Compounds and methods for treating oxalate-related diseases | OXALURX, INC. (US) | 2022-07-19 | — | — | US | disclosed |
| US-20200390778-A1 | COMPOUNDS AND METHODS FOR TREATING OXALATE-RELATED DISEASES | OXALURX, INC. | 2020-12-17 | — | — | US | disclosed |
| CN-111518044-A | Alkoxy isoxazole derivative and preparation method and application thereof | 华东师范大学 | 2020-08-11 | — | — | CN | disclosed |
| WO-2019165159-A1 | COMPOUNDS AND METHODS FOR TREATING OXALATE-RELATED DISEASES | OXALURX, INC. (US) | 2019-08-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200390778-A1 | COMPOUNDS AND METHODS FOR TREATING OXALATE-RELATED DISEASES | XDH, PNPO, LOX | ESR1 4780/4885ABL1 3986/4885ABCB1 2152/4885 |
| US-11389456-B2 | Compounds and methods for treating oxalate-related diseases | XDH, PNPO, LOX | ESR1 4780/4885ABL1 3986/4885ABCB1 2152/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.